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ABSTRACT 
 Developmental and epileptic encephalopathies (DEE) are characterized by the co-occurrence of 
epilepsy and intellectual disability (ID), typically with developmental plateauing or regression 
associated with frequent epileptiform activity. The cause of DEE remains unknown in the majority of 
cases. We performed whole-genome sequencing (WGS) in 197 individuals with unexplained DEE and 
pharmaco-resistant seizures and in their unaffected parents. We focused our attention on de novo 
mutations (DNMs) and identified candidate genes containing such variants. We sought to identify 
additional subjects with DNMs in these genes by performing targeted sequencing in another series of 
individuals with DEE and by mining various sequencing datasets. We also performed meta-analyses to 
document enrichment of DNMs in candidate genes by leveraging our WGS dataset with those of 
several DEE/ID series. By combining these strategies, we were able to provide a causal link between 
DEE and the following genes: NTRK2, GABRB2, CLTC, DHDDS, NUS1, RAB11A, GABBR2 and 
SNAP25. Overall, we established a molecular diagnosis in 63/197 (32%) individuals of our WGS 
series. The main cause of DEE in these individuals was de novo point mutations (53/63 solved cases), 
followed by inherited mutations (6/63 solved cases) and de novo CNVs (4/63 solved cases). De novo 
missense variants explained a larger proportion of individuals in our series than in other series that 
were primarily ascertained because of ID. Moreover, these DNMs were more frequently recurrent than 
those identified in ID series. These observations indicate that the genetic landscape of DEE might be 
different from that of ID without epilepsy. 
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INTRODUCTION 
Epilepsy is often associated with major comorbidities, most frequently intellectual disability 
(ID), which affects 25% of children with epilepsy.1,2 Conversely, the frequency of life-time history of 
epilepsy ranges from 7-15% for individuals with mild to moderate ID to 45-82% for those with severe 
ID.3 The co-occurrence of epilepsy and ID may involve at least two non-exclusive mechanisms. In 
some cases, uncontrolled seizures can be detrimental to developing cortical networks, leading to 
regression and poor cognitive outcomes in children.4 The term “epileptic encephalopathy” (EE) has 
been used to designate disorders where the epileptic activity itself contributes to cognitive slowing or 
regression, and can occur in a child with or without preexisting developmental delay.5 In other 
instances, a single genetic or environmental process is sufficient to induce both seizures and cognitive 
impairment.6 For instance, mutations that induce specific synaptic defects might result in aberrant 
connectivity and seizures as well as alter synaptic plasticity and cause learning disabilities. The term 
“developmental encephalopathy” (DE)” has been proposed to designate disorders where developmental 
delay emerges prior to the presence of epileptic activity or in the presence of infrequent epileptic 
activity.5 Because it is not always easy to dissect the contribution of each of these mechanisms and 
because some genetic disorders can involve both mechanisms in the same or in different individuals, 
the term ‘developmental and epileptic encephalopathy’ (DEE) has been coined to refer to conditions 
characterized by both ID and epilepsy where both mechanisms may play a role.5  
Recently, parent-child exome sequencing studies in sporadic DEE cases have shown that de 
novo mutations (DNMs) are an important cause of DEE. However, only a minority of the studied cases 
were solved by these approaches, thus underlining the genetic heterogeneity of DEE and the need to 
sequence large cohorts to increase the power to identify novel genes associated with DEE.7,8 With an 
average of ~1 DNM affecting the coding sequence of an individual, one of the challenges has been to 
determine whether the candidate DNMs are pathogenic or coincidental. To address this, Samocha et al. 
(2014) published a statistical framework that determined the rate of de novo variants per gene per class 
of variant [e.g., missense, nonsense, frameshift, canonical splice site (CSS)] that could be used to 
determine whether there is gene enrichment for a particular variant class in the studied cohort, thus 
providing evidence that the observed DNMs are likely implicated in the disease.9 This strategy was 
recently successfully employed in meta-analyses of DNMs identified from various ID and/or 
developmental disorder sequenced trios to identify genes enriched in DNMs in these cohorts.10,11 
In this study, we performed whole genome sequencing (WGS) on 197 DEE individuals and 
their unaffected parents. We focused our analyses on DNMs [single nucleotide variations (SNVs), 
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small insertions/deletions (indels)] and copy number variations (CNVs) affecting coding or splice site 
regions). To identify genes implicated in DEE, we performed meta-analyses combining the DNMs 
identified in our series along with those found in other studies of DEE or ID trios and looked for genes 
statistically enriched in DNMs. We also performed targeted sequencing and leveraged our network of 
collaborators and gene-matching tools to find additional similarly affected cases with DNMs in some of 
our prioritized genes, thus providing additional support for their implication in the disease. Based on 
these collective approaches, we provide herein evidence implicating DNMs in 8 genes in DEE. 
 
SUBJECTS AND METHODS 
Subjects. The DEE series screened by WGS (n=197 trios) was recruited at three centers in Canada: the 
Sainte-Justine University Hospital Center in Montreal (HSJ; 99 trios), the Toronto Western Hospital 
(TWH: 35 trios) and the Hospital for Sick Children in Toronto (HSC; 63 trios), after approval by the 
ethics research boards and obtaining informed consent from each participant or legal guardian. This 
series, referred to as the Canadian Epilepsy Network (CENet) DEE cohort, included subjects with 
diverse DEE phenotypes. The criteria used for the selection of these individuals were as follows: 1) 
intractable epilepsy defined as an absence of response to two appropriate and well-tolerated AEDs over 
a 6-month period and an average of at least one focal, generalized tonic-clonic, myoclonic, epileptic 
spasms, tonic, atonic or absence seizure per month during the period of poor control; 2) intellectual 
disability or global developmental delay (GDD); 3) absence of malformations or focal/multifocal 
structural abnormalities on brain MRI; and 4) absence of parental consanguinity and family history of 
epilepsy, intellectual disability or autism in first-degree relatives. Each individual was classified into a 
specific epilepsy syndrome when possible (Table S1). The majority (~90% of cases) had had array 
comparative genome hybridization performed on a clinical basis and only those with no pathogenic or 
possibly pathogenic CNVs were included. Many of the individuals were previously screened negative 
for mutations in various DEE gene panel tests.  A subset of candidate genes identified in the course of 
this study were sequenced in a cohort comprised of 595 individuals with EEs of unknown cause (Table 
S2), most of whom had been tested for mutations in genes previously associated with DEE as well as 
for pathogenic CNVs, as described.12 We were also able to recruit, through various collaborations, 
additional subjects with DNMs in candidate genes identified from clinical or research exomes. 
Informed consent was similarly obtained from these individuals or their legal guardians. 
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Whole genome sequencing. WGS sequencing was performed at the McGill University and Genome 
Quebec Innovation Center as part of the Illumina Genome Network (IGN) and according to the IGN 
standard procedure. Briefly, genomic DNA extracted from blood samples was subjected to an 
additional cleaning step using ZR-96 DNA Clean & ConcentratorTM-5 Kit (Zymo) and then used to 
generate sequencing libraries using the TrueSeq DNA PCR-free library preparation kit and according 
to the manufacturer’s procedure. Sequencing was done either on the HiSeq2000 (100 bp paired-end; 1 
genome/ 3 lanes) or the HiSeq2500 (125 bp paired-end; 1 genome/ 2 lanes) such that a minimum final 
coverage of 30x was attained after data processing.  
 
WGS data processing, variant calling and analyses. The Illumina sequencing reads were generated 
using bcl2fastq v1.8.4. Trimmomatic v0.32 was used to remove bad quality reads and to trim the read 
edges with a lower quality. The filtered reads were aligned to reference Homo sapiens assembly b37 
(GRCh37) using BWA-mem v0.7.10 to create a Binary Alignment Map file (.bam). Read set BAM 
files from different sequencing lanes for the same sample were merged into a single global BAM file 
using Picard v.1.123. Regions containing multiple base mismatches were realigned locally using 
Picard. Once local regions were realigned, Picard was also used to recalculate the read mate 
coordinates and to mark duplicates for removal. Individual base quality values were recalibrated using 
GATK v.3.3-0. Genotypes were called using GATK Haplotype-Caller and all variant calls were 
merged and recalibrated in three different sensitivity tranches using GATK and according to its 
recommended best practices. All variant sites were annotated using a custom version of Annovar.13 
Only variants whose positions were covered at ≥10x and supported by at least 4 variant reads 
constituting ≥ β5% of the total reads for each called position were considered. Rare variants included 
those present with a minor allele frequency (MAF) of ≤0.005 in 1000 Genomes, GoNL, ExAC vs 0.3, 
EVS (NHLBI Exome Sequencing Project; ESP) or ≤ 2% in the unaffected parents from the entire trio 
dataset. A variant segregation analysis (child-parents) was performed using an in-house script. Putative 
DNMs were identified by excluding those present in the genomes of the parents and those with a MAF 
≥ 0.001 in ExAC. Potential de novo variants outside the exonic and splice consensus regions were 
further excluded if present in small-repeat regions (for SNVs and indels), in Alu regions (for indels) or 
had a SNV variant quality recalibration score (VQSRT) of ≥ 99.90-to-100.00 or an indel VQSRT 
different than PASS. The sequencing reads carrying putative DNMs were inspected visually in each 
trio using the Integrative Genomics Viewer (IGV)14 to exclude obvious false positives or inherited 
variants. Putative DNMs affecting the coding and consensus splice regions were validated by Sanger 
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sequencing in the corresponding trio. 
 
CNV analyses. CNVs were identified using two algorithms: Lumpy, whose calls integrate multiple 
breakpoint signals, and PopSV, whose calls rely on deviation from normalized read-depths across 
samples.15,16 Default parameters were used unless otherwise specified. For PopSV, 5kb bin scans of the 
genome were used. CNV calls were filtered to exclude those with a size <1kb and qv (PopSV) or 
evidence set scores (Lumpy) ≤ 0.1%. CNVs falling in regions of segmental duplications were also 
excluded. To identify de novo CNVs, we excluded those present in any of the parents’ samples from 
the entire data set or in population controls from the 1000 Genomes or from the CNV map high quality 
datasets of common variants.17 De novo CNVs called by both Lumpy and PopSV were prioritized for 
validation. Potential de novo CNVs detected by only 1 algorithm, and thus likely enriched in false 
positives, were considered for validation only if they affected exonic regions and if they could not be 
ruled out as inherited or false positives upon visual inspection by IGV of the reads near the breakpoints. 
CNVs were validated in the trio using standard qPCR (Taqman assay) and/or by Sanger sequencing.  
 
Targeted sequencing using the Molecular Inversion Probes (MIPs) technique. Seven of our 
initially prioritized genes (DHDDS, RYR2, HECW2, GABRB2, NUS1, NTRK2 and CLTC) were 
selected for MIPs sequencing in a cohort of 595 individuals with DEE. We used a multiplex targeted 
capture strategy to target the coding exons and intron-exon boundaries (a minimum of five base pairs of 
flanking sequence) in each of the seven genes. Single molecule molecular inversion probes (smMIPs) 
were used as previously described18 with minor modifications detailed below. The molecular tag within 
the probe consisted of five random nucleotides that allowed for distinction of genomic molecules and a 
high-confidence consensus call. Library preparation remained the same as described by O’Roak et al. 
(2012)19 except the ratio of probe to genomic DNA was adjusted to 2,000:1, a tenfold increase than 
previously reported. Sequencing was performed on an Illumina HiSeq2500 to generate 100 base pair 
pair-end reads. Raw read mapping and processing were performed as previously described.12 Private 
variants (absent from SNP public databases: ExAC v0.3, EVS, and 1000 Genomes) predicted to affect 
the protein sequence (missense, nonsense, indels, and canonical splice sites) were validated using 
Sanger sequencing in the proband and the parents.  
 
Gene-specific DNM enrichment. We used DenovolyzeR open access program to assess whether a 
specific gene is enriched in DNMs in subjects with DEE and/or GDD/ID.20 This R package program is 
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based on gene-specific mutation rates.9 DNM gene specific p-values for loss-of-function variants (LoF: 
nonsense, CSS, frameshift indels) and functional variants (missense + LoF) calculated by DenovolyzeR 
were further corrected for multiple testing based on the 19 618 genes with available mutation rates on 
which Denovolyzer based its calculation (Bonferroni correction) and the number of tests (2; for LoF 
and functional categories) (i.e, 2 x 19 618 = 39 236). A corrected p-value (c.p-value) <0.05 was 
considered statistically significant. To increase statistical power, a meta-analysis was performed 
combining DNMs identified herein along with those previously reported from trio whole exome 
sequencing (WES) done on other DEE cohorts.8,21,22 We also performed another meta-analysis 
combining DNMs from the DEE cohorts with those from exome or genome sequencing from published 
ID cohorts.10,11,23-28. Only studies consisting of more than 10 trios were included in these meta-analyses 
(Table S3). To further increase the power to detect DNM-gene enrichment in genes whose mutations 
are not yet an established cause of DEE, we applied a similar strategy as Lelieveld et al (2016)11 who 
excluded from their meta-analysis trios with DNMs found in their curated list of genes previously 
associated with ID. Therefore, we performed a meta-analysis after excluding trios with DNMs affecting 
the autosomal dominant or X-linked genes mentioned in this list  (n = 572), which also includes genes 
associated with DEE, or trios with such mutations in 21 genes not reported in this list but subsequently 
found enriched with DNMs by Lelieveld et al. (2016) and/or by the recent Deciphering Developmental 
Disorders (DDD) trio sequencing study.10,11   
 
Clustering of de novo missense variants. We used the open source program Denovonear used in the 
DDD Study10,29 to calculate the probability of the proximity of de novo missense variants in genes of 
interest based on 1 million simulations weighted by the context trinucleotide rates. We considered a p-
value < 0.01 as statistically significant. 
 
RESULTS 
We performed WGS on 197 individuals with DEE and their unaffected parents. The average 
coverage of the genomes was 37.9x, with 99% of the genome (GRCh37) bases covered at ≥10x (Figure 
S1). The average number of SNVs and indels per genome was ~ 4 182 490 and ~23 532, respectively 
(Table S4). The average number of CNVs per subject, excluding those in segmentally duplicated 
regions, varied between 275 (PopSV) and 400 (Lumpy). In total, we detected an average of 66 high 
quality DNMs (61 SNVs, 5 indels) that passed IGV inspection (~75% of total DNMs calls) per 
individual, translating into a mutation rate of ~1.2x10-8 DNMs per diploid genome/generation, which is 
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in the range reported from other WGS trio studies.24,30-32  
We next focused our attention on the putative DNMs affecting the coding and the CSS that 
passed IGV inspection. We were able to validate by Sanger sequencing 95% of these calls. In total, 288 
DNMs were validated (1.46 DNM/trio), representing an average of ~1.37 de novo SNVs and 0.09 
indels per individual, which is in the range of what was observed in a previous WES study of DEE trios 
(Table S5).8 We did not detect any DNM in the coding or CSS regions of 39 probands (20%) (Figure 
S2A). Considering only de novo SNVs, 7.8% are predicted to cause a loss of function (nonsense and 
CSS variants) while 72% to cause a missense change (Figure S2B). We compared the de novo SNV 
rates observed in our DEE individuals with those observed in unaffected siblings of individuals with 
autism spectrum disorders (ASD; 66.5% missense, 4.8% LoF)33 or in Icelandic controls (82% 
missense, 2.7% LoF).32 We found an excess of LoF SNVs in our EE subjects when compared to these 
control sibling exomes (p = 0.03, binomial exact test) or Icelandic genomes (p = 0.00002; binomial 
exact test), suggesting that a subset of these variants contributes to the disease. 
We also searched for de novo CNVs. In total, 12 CNVs were called as de novo by both Lumpy 
and PopSV, all of which were successfully validated by qPCR and/or Sanger sequencing. In addition, 
35 putative de novo CNVs encompassing exonic regions were identified by only one of the algorithms; 
6 of these putative CNVs were confirmed de novo by qPCR, 17 were inherited and 12 were false 
positives. In total, 10/18 validated de novo CNVs affected exonic regions, including 5 deletions and 5 
duplications (Table S6).    
 
Likely pathogenic variants identified in the CENet series 
 For all DNMs and rare recessive variants (bi-allelic, X-linked hemizygous) affecting the coding 
regions or CSS, we assessed the involvement of the corresponding genes in epilepsy or related 
neurodevelopmental disorders by searching Pubmed [Gene name and (“epileptic encephalopathy” or 
“epilepsy” or “seizure” or “mental retardation” or “intellectual disability”)] and verifying the gene’s 
OMIM description. Using the ACMG 2015 guidelines for sequence variant interpretation,34 we initially 
identified pathogenic or likely pathogenic variants in 50/197 subjects (25%) in genes which, when 
mutated, have been shown to cause DEE and/or ID. Of these, 88% were explained by DNMs and 12% 
were caused by inherited recessive mutations (Tables 1, S5 and S7).  
We also identified pathogenic de novo CNVs in 3 individuals, including a 8 Mb deletion 
encompassing PCDH19 (OMIM 300460) in a female individual, a 5.2 Mb duplication corresponding to 
the 15q11-q13 region located between the recurrent breakpoints BP2-BP3 and a 3.4 kb exonic deletion 
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of DNMT3A (OMIM 615879), all of which have been previously associated with ID and/or epilepsy. 
 
Targeted MIPs sequencing  
From the WGS results of our first 120 DEE trios, we prioritized 7 of our best candidate genes 
(CLTC, DHDDS, GABRB2, HECW2, NTRK2, RYR2 and NUS1) for targeted resequencing in 595 
unsolved DEE cases. These genes were selected based on the documentation of predicted-damaging 
DNMs in at least 2 unsolved individuals from the CENet series or in 1 unsolved individual from the 
CENet series and in at least 1 previously reported case with DEE and/or ID. Exon-1 of NUS1 was 
excluded from the analysis because it was poorly covered across the samples (18% of the target bases 
at ≥10x), possibly due to its high GC content. On average, 90% of the target bases were covered at 
≥10x in 476 samples. Reduced coverage was obtained in the remaining 119 cases such that only 70% 
of the target bases reached the ≥10x, probably due to poor DNA quality. Four predicted-damaging 
missense variants absent from ExAC were identified, each in a single DEE subject, in NTRK2 
(NM_006180.4:c.1301A>G: p.Tyr434Cys), GABRB2 (NM_021911.2:c.730T>C:p.Tyr244His and  
c.911C>T: p.Ala304Val), and HECW2 (NM_020760.1:c.4484G>A: p.Arg1495Lys). These variants 
were validated as de novo by Sanger sequencing. Interestingly, 2 of the DNMs affecting GABRB2 
(p.Tyr244His) and NTRK2 (p.Tyr434Cys) were also recurrent in the CENet series. The missense 
(p.Arg1495Lys) in HECW2 is also recurrent as it was previously reported as a de novo variant in a 
DDD case.10 Recently DNMs in HECW2 have been shown to cause DEE.25,35  
 
Involvement of NTRK2, GABRB2, CLTC, DHDDS and NUS1 in DEE 
  We next sought to identify additional individuals with DEE or ID who carry DNMs in the 
candidate genes that were prioritized for MIPs sequencing by mining GeneMatcher36 and 
DDD/Decipher37 and by contacting our network of collaborators. Through this approach, we were able 
to obtain additional supporting evidence for the involvement of the following genes in DEE.   
NTRK2. Our trio WGS and targeted sequencing strategy led to the identification of 3 
individuals with DEE carrying de novo predicted-damaging missense variants in NTRK2 
(NM_006180.4), including an individual with c.2159C>T (p.Thr720Ile) variant and 2 unrelated 
individuals with the same c.1301A>G (p.Tyr434Cys) variant. In addition, we identified 2 other 
individuals with the de novo p.Tyr434Cys missense through clinical WES.  
In total, we identified 4 individuals with the p.Tyr434Cys missense. All subjects with this 
missense variant had severe GDD/ID and optic nerve hypoplasia with visual impairment, and 3 had 
12 
 
significant feeding impairment (Table 2; Supplemental Note). Three of them presented with epileptic 
spasms in the first few months of life and subsequently developed intractable seizures of various types 
associated with multifocal epileptic activity on EEG whereas the remaining individual had startle-like 
myoclonic events at 12 hours of life and developed, at 5 years of age, focal seizures with impaired 
awareness occasionally evolving towards bilateral tonic clonic seizures. Clustering analysis using the 
Denovonear algorithm indicated that the presence of the p.Tyr434Cys variant in 4 individuals with 
similar phenotypes is statistically significant (p = 0.0001). 
The subject with the p.Thr720Ile missense mutation had moderate-severe ID, ASD and 
intractable generalized tonic-clonic and focal seizures with impaired awareness starting at the age of 
2.5 years. Unlike the individuals with the p.Tyr434Cys missense, she had hyperphagia and early-onset 
obesity from the age of 3 years. Interestingly, Yeo et al. (2004) reported an individual carrying the de 
novo c.2165A>G (p.Tyr722Cys) variant, affecting an amino acid residue adjacent to Thr720, who 
presented with a similar phenotype as that of our subject, including excessive weight gain, moderate 
ID, language delay, autistic features, hypotonia and seizures.38  
NTRK2 encodes the TrkB receptor, a member of the neurotrophin receptor tyrosine kinase 
family.39 TrkB has high affinity for the brain derived neurotrophic factor (BDNF) and for neurotrophin-
4 (NT4). BDNF-TrkB signalling is a critical regulator of neuronal development and function.40 The 
p.Tyr434Cys variant is located at the beginning of the transmembrane domain (TM) of NTRK2 (Figure 
1A). The fact that this de novo variant has been identified in 4 cases with a similar phenotype suggests 
that it confers a specific property to the protein, possibly via a gain-of-function or a dominant-negative 
mechanism. The p.Thr720Ile and p.Tyr722Cys variants cluster in the catalytic domain of NTRK2 
(Figure 1A). In vitro studies indicate that p.Tyr722Cys impairs BDNF-induced TRKB receptor 
autophosphorylation and downstream signalling.38 It is currently unknown whether the p.Thr720Ile 
affects NTRKβ’s function in a similar way but its proximity to p.Tyr722Cys and the similarity in the 
phenotype of both individuals carrying these mutations suggest that this could be the case. 
Interestingly, mice expressing 25% of TRKB levels are hyperphagic and have excessive weight.41 
Altogether, our findings unequivocally show that DNMs in NTRK2 cause DEE. 
GABRB2. Our WGS and MIPs screens identified 3 individuals with DEE carrying DNMs in 
GABRB2 (NM_021911.2), including the c.911C>T (p.Ala304Val) variant in one subject and the 
recurrent c.730T>C (p.Tyr244His) variant in 2 subjects. Two other individuals with DNMs in GABRB2 
were identified by the DDD study10, one with the c.830T>C (p.Leu277Ser) variant and another with the 
c.373G>A (p.Asp125Asn) variant. We also identified from WES and targeted gene panel sequencing 6 
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individuals with de novo missense variants in GABRB2, including one with the same c.830T>C 
(p.Leu277Ser) as that found in the DDD subject, one with c.851C>A (p.Thr284Lys), one with 
c.878G>C (p.Arg293Pro), one with a missense (c.908A>G:p.Lys303Arg) adjacent to c.911C>T 
(p.Ala304Val) identified in our MIPs screen, one with c.946G>A (p.Val316Ile) and one with a de novo 
c.236T>C (p.Met79Thr) variant. This latter individual was previously reported with a de novo 
frameshift in CHAMP1 (NM_032436.2: c.1876_1877delAG:p.Ser626Leufs), which also likely 
contributes to the cognitive impairment of the subject (F3-II.1 in Isidor et al. 2016).42 All of these de 
novo missense variants are predicted damaging (polyphen-2, SIFT and CADD). Their localization in 
GABRB2 is shown in Figure 1B.  
We were able to obtain detailed clinical information for all of these 11 individuals (Table 3; 
Supplemental Note). They all displayed moderate to severe ID (or severe GDD), with the exception of 
the individual with the p.Val316Ile variant who achieved normal milestones at 21 months of age. Most 
cases had microcephaly (n=7/11), which was acquired in 6 individuals and congenital in the 7th. Most 
individuals developed refractory seizures within the first year of life, with a preponderance of 
myoclonic seizures and absences, sometimes evolving towards myoclonic status epilepticus or non-
convulsive status epilepticus. Some individuals developed focal seizures with impaired awareness or 
autonomic seizures, tonic, atonic seizures, and rarely generalized tonic-clonic seizures. In half of the 
cases, the epilepsy remained refractory despite multiple drug trials. Two individuals were trialled on 
vigabatrin with marked deterioration. Responses were observed to lamotrigine, valproate, levetiracetam 
or high dose steroids in 5 individuals. Axial hypotonia, spasticity, dystonia and choreoathetosis appear 
to be common features. Cortical visual impairment was present in 3/11 cases. Brain MRIs were usually 
normal, except for delayed myelination or diffuse T2 hypersignal in the subcortical white matter, as 
noted in 3 individuals.  
GABRB2 encodes the ȕβ subunit of the GABAA receptor, a neuronal pentameric ionotropic 
ligand-gated chloride channel that induces synaptic inhibition when activated by its agonist GABA.43 
Mutations in other GABAA receptor subunits encoding GABRA1 (OMIM 137160), GABRB1 (OMIM 
137190), GABRB3 (OMIM 137192) and GABRG2 (OMIM 137164) are established causes of DEE. 
Three cases with DNMs in GABRB2 and detailed phenotypic information have been previously 
published: one of these subjects, who carries the DNM p.Met79Thr, also found in one of our cases, 
showed generalized seizures and moderate ID, another one displayed ID, seizures (of unspecified type) 
and cortical visual impairment (c.754C>G: p.Pro252Ala) and the last one was found to have early-
onset myoclonic encephalopathy (c.859A>C: p.Thr287Pro) .44 45,46 Four additional cases with de novo 
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missense in GABRB2, including c.845T>C (p.Val282Ala), c.863T>G (p.Ile288Ser), c.909G>T 
(p.Lys303Asn), c.911C>T (p.Ala304Val), have been reported.47-49 The amino acid residues affected by 
the latter two of these DNMs (p.Lys303Asn and p.Ala304Val) were also found mutated in our series. 
These 4 individuals appear to show ID/GDD and epilepsy but no detailed clinical information was 
available. 
Out of the 13 DNMs in GABRB2 previously reported or described herein, 10 are clustered 
within a stretch of 60 amino acids (positions 244-304) encompassing 3 transmembrane domains and/or 
their boundaries (p-value = 0.000002, Denovonear) (Figure 1B). These clustering mutations appear to 
be mostly associated with severe GDD/ID and, with the exception of p.Arg293Pro, intractable 
generalized seizures and DEE. So far only 1 of these de novo missense variants, p.Thr287Pro, has been 
functionally tested in transfected HEK293 and found to reduce cell surface expression and peak current 
amplitudes of GABAA channels.46 It is currently unknown whether the other de novo missense variants 
in GABRB2 behave similarly to p.Thr287Pro, especially the closely clustering or recurrent ones 
(p.Tyr244His, p.Leu277Ser, p.Lys303Leu and p.Ala304Val), which may confer specific property to the 
protein such as gain-of-function or dominant negative effects. Collectively, the cases with DNM in 
GABRB2 reported here along with the previously published ones confirm that de novo missense 
mutations in GABRB2 can cause a DEE phenotype.  
CLTC. Our WGS trio screen identified a de novo frameshift variant in the CLTC gene 
(NM_004859.3), c.4575dupA (p.Val1526fs*18), in an individual with moderate ID associated with 
severe refractory seizures (absences, myoclonic, tonic, generalized tonic-clonic and focal seizures). We 
obtained detailed clinical information on 11 additional cases with DNMs in CLTC, 4 of which were 
identified by the DDD study10, while the other 7 we identified through clinical WES (Table 4; 
Supplemental Note). We were able to obtain detailed clinical information for all of these 12 
individuals. Most individuals presented with early-onset hypotonia and GDD, evolving towards mild to 
severe ID (or borderline intelligence). Four individuals also developed ataxia. When performed, 
neuromuscular investigations (EMG, biopsy) were negative. Two individuals had pharmaco-resistant 
epilepsy, with preponderance of myoclonic and generalized tonic-clonic seizures. One individual had 
one isolated seizure and is now seizure-free after being weaned from medication. Two other individuals 
had severe GDD/ID with seizures, starting between the ages of 1 and 2 years, that were well controlled 
with valproate or levetiracetam. Interestingly, 3 of the ID cases (one sequenced by the CAUSES Study, 
a second in the context of the Undiagnosed Patient Program [UPP] at OPBG, Rome) had a recurrent de 
novo missense (c.2669C>T: p.Pro890Leu), which was also reported in a DDD trio for which we were 
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not able to obtain phenotypic information. The presence of the same DNM in CLTC in 4 independent 
cases was statistically significant for missense clustering (p = 0.0000001, Denovonear). The positions 
of these various DNMs in CLTC are shown in Figure 1C. 
CLTC encodes the widely expressed clathrin heavy chain 1, which is involved in endocytosis, 
intracellular trafficking and synaptic recycling.50,51 Recently, a de novo frameshift in CLTC 
(c.2737_2738dupGA p.Asp913Glufs*59) was reported in a subject with GDD, unclassified epilepsy 
and dysmorphic features.52,53 Two additional DNMs were also reported by Leliveld et al. (2016)11 from 
their study of 800 probands with ID, including c.4615C>T (p.Glu1539*) and c.3621_3623del 
(p.Asp1207del), the latter being also identified in one of our DEE cases. CLTC is predicted intolerant 
to LoF mutations with a pLi score of 1.00 according to ExAC.54 The phenotypic spectrum associated 
with these cases is heterogeneous ranging from mild ID or learning disability to severe ID or DEE. 
Interestingly, individuals with refractory epilepsy were found to carry mutations in the first section of 
the clathrin LC binding domain, whereas de novo truncating mutations at the C-terminus of CLTC 
tended to be associated with hypotonia, GDD and ID (Figure 1C).   
DHDDS. WGS identified a de novo missense variant (c.110G>A: p.Arg37His) in DHDDS 
(NM_024887.3) in of one of our DEE individuals (HSJ0762). We identified, by clinical WES, another 
individual with EE who carries the same de novo p.Arg37His. Interestingly, this missense lies adjacent 
to p.Arg38His, which has been reported in a DEE case from the Epi4K study.7 Clustering analysis 
indicated that the presence of these two de novo mutations in 3 individuals is statistically significant 
(p=0.0005, Denovonear). In addition, we identified by clinical/research WES two other individuals 
with DEE and a de novo missense c.632G>A (p.Arg211Gln) in DHDDS and obtained detailed clinical 
information on a third subject, also with the same de novo p.Arg211Gln (indvNCJ herein), who was 
previously reported in a recent WES study of ID trios.11 The positions of these various identified 
DNMs in DHDDS are shown in Figure 1D and their associated phenotype are summarized in Table 5 
and detailed in the Supplemental Note. 
 These 5 individuals with DNMs in DHDDS presented with a generalized epilepsy disorder with 
myoclonic seizures, either as myoclonic absences or as isolated cortical myoclonus, sometimes with 
light-sensitivity or fever susceptibility. Two of these individuals also presented other generalized 
seizure types, including atonic seizures or generalized tonic-clonic seizures. In 3 cases, the EEG 
revealed clear generalized spike-wave discharges (in one case with additional photosensitivity). The 
seizures were aggravated by levetiracetam in 2 cases, but favourable responses to valproic acid were 
observed. Interestingly, all cases presented with marked hypotonia and 4 had mixed movement 
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disorders including ataxia, tremors and dystonia.  
DHDDS encodes dehydrodolichyl diphosphate synthase (also known as hCIT), which is 
essential for dolichol monophosphate (Dol-P) synthesis and global N-linked glycosylation.55 The 
Arg37 and Arg38 residues fall into an evolutionary conserved stretch of 5 amino-acids (pos. 34-38) 
corresponding to the catalytic domain of the enzyme (Figure 1D). Based on the crystal structure and 
mutagenesis studies done on the bacterial Dhdds enzyme (M. luteus ndecaprenyl diphosphate synthase, 
UDPS), the Arg203 residue, which is equivalent to Arg211 in the human DHDDS, is critical for the 
homoallylic binding to the substrate isopentenyl diphosphate.56,57 The identification of recurrent or 
clustering DNMs in individuals with a similar phenotype in DHDDS is highly suggestive of 
pathogenicity. 
A homozygous missense variant (c.124A>G: p.Lys42Glu) was previously found in DHDDS in 
consanguineous families with retinitis pigmentosa.58,59 In addition, bi-allelic truncating/splicing 
variants in DHDDS were reported in a case of type I congenital disorder of glycosylation with severe 
GDD and refractory seizures.60 We hypothesize that null alleles of DHDDS disrupt brain development 
only in in the context of a recessive genotype whereas the DNMs documented in our study cause DEE 
via a dominant-negative or gain-of-function mechanism.    
 NUS1. We identified 2 DNMs in NUS1 (NM_138459.3), each in individuals from our WGS trio 
study, including a frameshift variant in exon-1 (c.128_141dup: p.Val48Profs*7) and a ~1.3 kb deletion 
encompassing the entire exon-2 of NUS1 in the other case. In addition, we identified a de novo 
truncating variant in NUS1 (c.743delA: p.Asp248Alafs*4) by clinical WES in an individual with DEE 
(Table 5, Supplemental Note; Figure 1E). These cases with DNMs in NUS1 all presented with GDD (or 
isolated motor delay), evolving towards mild to severe ID. Furthermore, they all presented generalized 
myoclonic seizures (in one case with myoclonic status epilepticus), combined with myoclonic absences 
in 2 cases. In all cases, other generalized seizure types were observed, including atonic seizures (drop 
attacks) or generalized tonic-clonic seizures. EEGs revealed either generalized epileptic activity or bi-
frontal epileptic discharges.  Movement disorders were also common, including tremor (2 cases) and 
ataxia (one case). Together, this clinical phenotype is highly reminiscent of the one we observed in 
cases with DNMs in DHDDS.  
 NUS1 encodes the Nogo-B receptor (NgBR) which physically interacts with DHDDS to 
stabilize the dehydrodolichyl diphosphate synthase complex and potentiate its enzymatic activity.55,61 
Both indel mutations identified in this study affect upstream exons, thus having the potential of 
inducing nonsense mediated decay of the transcript. In addition, both variants are predicted to abolish 
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the conserved C-terminal domain, which is required for the interaction with DHDDS.61 The deletion of 
exon-2 causes an in-frame deletion of amino acids 139-180 leading to the loss of TM3 which is critical 
for the proper topology of NUS1. Previously, a homozygous missense mutation affecting its C-
terminus (c.869G>A: p.Arg290His) was identified in 2 siblings with type 1a congenital disorder of 
glycosylation and a severe phenotype of early onset refractory epilepsy, congenital scoliosis, 
developmental delay with hypotonia, microcephaly, hearing and visual impairment as well as severe 
cortical atrophy.62 This mutation was found to decrease cis-PTase activity when expressed with hCIT 
(DHDDS) in yeast. In addition, Szafrans et al. (2015) reported cases with early onset seizures and 
microdeletions of chromosome 6q22.1, which are centered on a 250 kb critical region that only 
includes NUS1 and the promoter of SLC35F1.63 
Collectively, our finding of DEE cases with 2 truncating DNMs and 1 de novo whole exon 
deletion in NUS1, the reported DEE cases with NUS1 microdeletions and the fact that NUS1 is a 
functional direct interactor of DHDDS suggest that heterozygous mutations in NUS1 can cause DEE, 
possibly via a mechanism of haploinsufficiency. This is in agreement with the fact that NUS1 does not 
tolerate LoF variants as suggested by the ExAC dataset where no such LoF mutations were reported 
(pLi = 0.87).54 The more severe phenotype previously observed in the siblings with the homozygous 
p.Arg290His mutation could be due to a more dramatic reduction in NUS1 activity due to the recessive 
nature of a potentially hypomorphic mutation. Failure to identify other cases with NUS1 truncating 
mutations from the MIPs screen or other EE published trios maybe in part due to reduced capture 
efficiency of exon-1, which encodes 137/293 amino acids of NUS1 (~ 47%). Indeed, in the ExAC 
database, exon-1 of NUS1 is, on average, poorly covered by WES compared to the rest of exons of this 
gene. 
  
Meta-analyses of DNMs from DEE and DEE-ID cohorts 
 In order to further assess the involvement of various candidate genes in DEE, we sought to 
determine whether DNMs were enriched in certain genes in series of affected individuals by taking 
advantage of a statistical framework that is based on the use of gene-specific mutation rates.9 To 
increase power, we meta-analyzed DNMs from our DEE cohort along with DNMs from published 
WES DEE trio studies (combined DEE trios = 624; Table S3). In total, 12 genes were found to be 
statistically enriched for LoF and/or functional DNMs (Table 6); mutations in all of these genes are 
now considered causative of DEE. 
As epilepsy is a frequent co-morbidity of ID, we performed a second meta-analysis combining 
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the DNMs from published ID trios with those from the DEE-cohorts used above (DEE-ID cohorts: 
5948 trios: 7778 DNMs). In total, 111 genes were found enriched for functional and/or LoF DNMs, 37 
of which were found mutated in at least one DEE case (Table S8). Interestingly, DNM enrichment has 
not been previously documented for 22/111 genes, including 9 genes that have either not been directly 
associated with ID or DEE [(BTF3 (OMIM 602542), CHD3 (OMIM 602120), FBXO11 (OMIM 
607871), PLK5, SETD1B (OMIM 611055), SF1 (OMIM 601516)] or have been described only in 
single or few cases, therefore representing candidates pending additional evidence [(CLTC (OMIM 
118955),52 GABBR2 (OMIM 607340),12,27 PHIP (OMIM 612870)].64 Among these only GABBR2, 
PHIP and CLTC had some DNMs in DEE cases, while the rest had DNMs only in the ID cohorts 
(Table S8). 
Lelieveld et al. (2016) recently showed increased power to detect novel ID-associated genes in a 
meta-analysis after excluding individuals with DNMs in genes previously found to be causally linked 
to ID.11 We applied here a similar strategy to both the DEE-ID cohort and excluded individuals with 
DNMs in any of the genes mentioned in the list established by these authors.11 We also removed the 
cases with DNMs in genes that showed DNM enrichment from the recent meta-analyses done on 
ID/developmental disorder trios.10,11 This retained 4424 trios from the combined DEE-ID cohorts. As a 
result, 3 additional genes from the DEE-ID cohort showed modest but significant functional DNM 
enrichment, including GABRB2 (OMIM 600232; c.p-value = 0.036), RAB11A (OMIM 605570, c.p-
value = 0.036) and SNAP25 (OMIM 600322, c.p-value = 0.042), all of which were found with 
predicted-damaging DNMs in individuals from our CENet DEE cohort as well as in individuals from 
the ID cohorts.  
 
Additional supporting evidence for the involvement of RAB11A, GABBR2, SNAP25 in DEE 
 Our meta-analyses of EE-ID trios showed significant enrichment of DNMs in GABBR2, PHIP, 
CLTC, RAB11A, SNAP25 and GABRB2, genes whose mutations have not yet been confirmed as a cause 
of DEE.  With the exception of PHIP, we found predicted-damaging DNMs in all of these genes in 
individuals from the CENet series. We further validated the involvement of GABRB2 and CLTC in 
DEE by identifying additional cases in the context of our MIP screen or other WGS/WES studies (see 
above). As shown below, we also provide additional evidence for the involvement of RAB11A, and 
GABBR2 and SNAP25 in DEE. 
 RAB11A (NM_004663.3). We found a de novo predicted-damaging missense variant in 
RAB11A (c.244C>T: p.Arg82Cys) in a CENet case with refractory epileptic spasms and erratic 
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myoclonus with developmental regression. She subsequently developed focal seizures and severe ID. 
We also identified by WES another predicted-damaging de novo missense in RAB11A (c.71A>G: 
p.Lys24Arg) in an individual with moderate GDD and an abnormal EEG but with no seizures reported 
so far. Three additional individuals with DNMs in RAB11A were identified in the context of the DDD 
study10, including 2 individuals with the same variant (c.461C>T: p.Ser154Leu) and another individual 
with a different variant (c.39A>C: p.Lys13Asn). We were able to obtain detailed clinical information 
on the cases with the p.Ser154Leu variant that both showed moderate GDD without epilepsy. The other 
individual from the DDD study had abnormalities of the nervous system according to the Decipher 
database but we could not get additional clinical information. Brain atrophy and/or abnormalities of the 
corpus callosum were noted for three of the individuals with available MRI information (Table 7; 
Supplemental Note). 
 RAB11A encodes a GTPase that regulates the recycling of a wide range of receptors at the cell 
surface.65 Interestingly, RAB11A regulates synaptic plasticity by modulating the endocytic recycling of 
NTRK2 and AMPA receptors at the post-synaptic membrane of neurons.66-68 The highly conserved 
Arg82 residue is located in the nucleotide-sensitive switch domain II of RAB11A and is involved in 
binding to the RAB11A effector FIP3.69,70 The p.Lys24Arg, p.Lys13Asn and p.Ser154Leu mutations 
do not affect any of the nucleotide-sensitive switch domains of RAB11A (Figure 1F). The fact that 
RAB11A is enriched in DNMs in the DEE-ID cohorts and found with a recurrent de novo missense in 2 
cases of the DDD cohort, suggests that DNMs in this gene can cause a DEE or ID phenotype.  
GABBR2. We identified from our WGS a de novo missense in GABBR2 (NM_005458.7), 
c.2077G>T (p.Gly693Trp), in one subject of our CENet cohort who presented with focal seizures with 
impaired awareness and later developed epileptic spasms while on carbamazepine. He remains with 
refractory focal and generalized tonic-clonic seizures, severe ID, severe limb and axial hypotonia and 
hyporeflexia (Table 7; supplemental Note). The Epi4K consortium reported 2 de novo predicted-
damaging missense variants (c.2114T>A: p.Ile705Asn and c.2084G>T: p.Ser695Ile) in GABBR2 in 
two unsolved cases with infantile spasms.8 Lopes et al. (2016) recently reported a de novo missense in 
GABBR2 (c.1699G>A: p.Ala567Thr) in an individual with severe ID and Rett syndrome-like features 
but no seizures.27  
GABBR2 encodes a Ȗ-aminobutyric acid type B receptor that inhibits neuronal activity through 
G protein-coupled second-messenger signaling, present both at the presynaptic and post-synaptic 
membrane where it regulates neurotransmitter release and the activity of ion channels.71 The receptor is 
the target of baclofen, a medication often used to treat spasticity. The hypotonia and hyporeflexia 
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observed in our case might therefore reflect underactivation at the neuromuscular junction or in spinal 
motor control centers. Interestingly, unlike the missense identified by Lopes et al., which affects 
transmembrane domain 3 (TM3) of GABBR2, the 3 DNMs in cases with infantile spasms cluster 
together in the TM6 of the protein (p = 0.001, Denovonear), suggesting that these TM6 mutations are 
specific for DEE. Meta-analysis of DNMs from DEE-ID cohorts showed an enrichment in functional 
DNMs in GABBR2, In addition to the subject with the c.1699G>A (p.Ala567Thr) variant from Lopes et 
al, the DDD cohort contained 2 other individuals with the p.Ala567Thr variant and one individual with 
a c.1181C>T (p.Thr394Met) variant that affects the N-terminal extracellular region of the receptor.10 
We conclude that de novo missense mutations in GABBR2 have the potential to cause DEE or ID with 
no seizures, depending perhaps on their location in the protein.  
SNAP25. We identified from our WGS a de novo missense in SNAP25 (NM_003081.3/ 
NM_130811.2:c.496G>T: p.Asp166Tyr) in a male with DEE. He presented with apneas, GDD, 
nocturnal generalized tonic-clonic seizures and focal seizures with impaired awareness and progressed 
towards moderate ID (Table 7, Supplemental Note).  SNAP25 is a member of the SNARE complex that 
is required for the exocytosis of neurotransmitters during synaptic transmission by mediating synaptic 
vesicle fusion.72,73 Developmentally regulated alternative splicing of 2 similar exon 5 sequences of 
SNAP25 generates 2 isoforms (a and b), differing only by 9 residues in this exon 5. Various mutant 
Snap25 mouse lines displayed cognitive deficit and seizures or susceptibility to seizures.74,75 SNAP25 
interacts with STXBP1, another SNARE synaptic protein in which mutations are known to cause 
DEE.26,76 So far, only 2 single cases have been published with de novo mutations in SNAP25, including 
one with a missense affecting both isoforms (NM_003081.3/ NM_130811.2: c.142G>T: Val48p.Phe) 
found in a case with DEE77 and another with a missense affecting a conserved residue in exon 5 of only 
SNAP25b (NM_130811.2: c.200T>A: p.Ile67Asn) in a girl showing congenital myasthenia, cerebellar 
ataxia, and ID.78 Both mutations affect the N-terminal t-SNARE coiled-coil homology domain of 
SNAP25. The de novo missense mutation identified in our cohort (p.Asp166Tyr) is predicted damaging 
(SIFT, polyphen-2, CADD) and alters a conserved residue in the second t-SNARE coiled-coil 
homology domain common to both isoforms (Figure 1H).  In addition, three DNMs in SNAP25 were 
recently reported in the DDD study [NM_130811.2: c.118A>G p.(Lys40Glu); c.127G>C 
(p.Gly43Arg); c.520C>T: p.(Gln174*)] but no detailed clinical information were available on these.10 
Collectively, these findings support the involvement of SNAP25 mutations in DEE. 
 
 
21 
 
Pattern of DNMs associated with DEE 
Out of the 53 pathogenic or likely pathogenic de novo point variants identified in our CENet 
series, 35 are missense and 15 are LoF, resulting in a missense/LoF ratio of 2.5 (Table S5). We 
examined the list of DNMs identified in the Epi4K series of individuals with DEE and found a similar 
ratio of pathogenic or likely pathogenic missense variants to LoFs (n= 56 DNMs; missense = 43, LoF = 
13 ratio; missense/LoF = 3.3).8 Interestingly, these observed de novo missense/LoF ratios of 
pathogenic/likely pathogenic variants in both the CENet (p = 0.004, 2-tailed Fischer’s exact test) and 
Epi4K (p=0.0004, 2-tailed Fischer’s Exact test) series were significantly increased when compared to 
those similarly observed in 192 moderate-to severe ID published trios (WES and WGS) with detailed 
phenotypic and pathogenic variant information (36 missense/42 LoF = 0.85).23,24,26,28 Remarkably, out 
of all the pathogenic/likely pathogenic DNMs identified in the CENet series (n =53), ~45% were also 
independently reported in ClinVar [n = 24 (19 missense and 5 LoF)] (Table S5). This rate of recurrent 
pathogenic/likely pathogenic DNMs was significantly higher in the CENet DEE series compared to 
that identified from the exomes/genomes of the 192 previously published moderate-to severe ID trios 
used in the above comparison [out of 80 pathogenic/likely pathogenic variants only 19 (13 missense, 6 
LoF) were also reported independently in ClinVar] (p = 0.0012, 2-tailed Fischer’s exact test)23,24,26,28.  
 
DISCUSSION 
In this study, we performed WGS on 197 individuals with DEE and their unaffected parents. 
We initially identified pathogenic variants in 53/197 cases (27%), including 50 cases with point 
mutations in genes previously found to be causally linked to DEE/ID, 1 with a recurrent pathogenic 
CNV (15q11-q13 duplication) and 2 cases with CNVs encompassing genes previously associated with 
ID or DEE (PCDH19 and DNMT3A). Moreover, we were able to explain DEE in 10 additional 
individuals from the series by identifying DNMs in candidate genes for which we provide additional 
evidence for their involvement in DEE (NTRK2, GABRB2, CLTC, DHDDS, NUS1, RAB11A, GABBR2 
and SNAP25). Overall, our approach allowed us to obtain a molecular diagnosis in 63/197 (32%) 
individuals. It is important to note that the diagnostic yield of WGS would have likely been higher in 
an unbiased series since many of our subjects had previously been screened by clinical targeted 
sequencing and/or array genomic hybridization. Interestingly, 2 of the 4 pathogenic de novo CNVs 
identified in our series would have been missed by clinical array genomic hybridization because of 
their size (˂ 5 kb), providing some support for the added value of WGS. 
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The main cause of DEE in our series was de novo point mutations (53/63 solved cases), the 
remaining cases being explained by inherited mutations (6/63 solved cases) or de novo CNVs (4/63 
solved cases). De novo missense variants explained a larger proportion of individuals with DEE in our 
series than individuals from other series that were primarily ascertained because of ID. Interestingly, 
more than half of these pathogenic missense mutations were recurrent, suggesting that at least a subset 
of them confer a specific property to the protein such as dominant-negative or gain-of-function effects. 
Shohat et al. (2017) recently showed that genes with LoF mutations compared to genes with missense 
mutations were associated with different pathways across neuro-developmental disorders such as ID, 
autism spectrum disorder and schizophrenia.79 For instance, genes with missense variants involved in 
neuro-developmental disorders code for proteins that show a higher number of protein interactions 
when compared to genes with LoFs. Altogether, this data raises the possibility that the genetic 
landscape of DEE is enriched for gene products that act as protein hubs. It would be important to 
understand why these hubs are specifically associated with DEE.  
Of the 8 genes highlighted herein for their involvement in DEE, we were not able to show de 
novo gene-enrichment for 3 of them, NTRK2, DHDDS and NUS1. However, the multiple occurrences 
of DNMs affecting the same conserved amino acid residues in NTRK2 and DHDDS in cases with a 
similar phenotype, nonetheless, represents a strong evidence implicating these genes in DEE. Indeed, 
other DEE-related genes with site-specific recurrent DNMs, such as GRIN2D (OMIM 300776) and 
FGF12 (OMIM 601513), did not also show DNM enrichment in our meta-analyses. Genetic forms of 
neuro-developmental disorders that are caused by recurrent DNMs associated with gain-of-function or 
dominant negative effects tend to be rare because there are typically a smaller number of variants that 
can confer such effects than variants that can induce haploinsufficiency. It is thus likely that meta-
analyses involving larger number of subjects will be necessary to identify these rare forms of DEE. No 
DNM enrichment was observed for NUS1 in our meta-analysis, possibly due to the poor capture of its 
exon-1, which represents almost half of the entire coding sequence of this gene. However, the 
identification of 3 DNMs in NUS1 (including 2 truncating variants and a microdeletion) in DEE cases 
with similar phenotypes and the fact that NUS1 is a functional direct interactor of DHDDS strongly 
support the involvement of this gene in DEE. 
Several of the DEE-related genes highlighted in this study code for proteins that interact 
directly or indirectly with other proteins encoded by genes associated with epilepsy. This is the case 
for: 1) DHDDS and NUS1, which form a complex for the synthesis of dolichol monophosphate 55,61; 2) 
SNAP25, which interacts with the DEE-associated STXBP1 for the docking of neurotransmitter 
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vesicles; and 3) RAB11A, which is involved in the endocytosis of NTRK2.68 In addition, GABRB2 
and GABBR2 both belong to the family of GABAergic receptors, which include other members 
involved in epilepsy [GABRA1 (OMIM 137160), GABRB1 (OMIM 137190), GABRB3 (OMIM 
137192) and GABRG2 (OMIM 137164)]. The identification of multiple genes acting along pathways or 
playing biological functions that have already been linked to epilepsy raise the possibility that many of 
the major pathways involved in DEE have been identified. Stratification of genetic forms of EE based 
on the involvement of these pathways may facilitate the development of tailored therapies. 
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Figure 1. Localisation of de novo mutations in protein domains of the genes of interest. A) 
GABRB2, B) CLTC, C) NUS1, D) NTRK2, E) DHDDS, SNAP25, GABBR2 and RAB11A. Recurrent 
DNMs are in italics and red font. The transmembrane domains of GABRB2 and GABBR2 are labeled 
1-4 and 1-7, respectively. TM, transmembrane domain; TD, trimerization domain; SP, Signal Peptide; 
LRRNT, Leucine Rich Repeat N-Terminal domain; LRR, Leucine-rich Repeats; LRRCT, Leucine Rich 
Repeat C-Terminal domain; IGC2, Immunoglobulin C-2 Type 1 domain; IGC2-2, Immunoglobulin C-
2-type 2 domain; Shc, SHC1 interaction domain; IPP, isopentenyl diphosphate binding site; CD, 
catalytic domain; FPP, farnesyl diphosphate binding site; SW, switch domain; CC, prenylation 
residues. 
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Table 1. Genes affected by pathogenic or likely pathogenic variants in the CENet cohort 
variant type genes whose mutations are an established cause of  DEE and/or ID  candidate genes  
DNMs (n=53) (n = 44) (n = 9) 
  missense SCN1A (3), SCN2A (3), SCN8A (4), KCNT1 (3), CACNA1A (2), GNAO1 (2),  
ATP1A3 (1), CDKL5 (1), COL4A1 (1), DDX3X (1), DNM1 (1), FGF12 (1), 
GABRG2 (1), HECW2 (1), KCNA2 (1), KCNQ2 (1), MED13L (1), MEF2C (1), 
NAA10 (1), PPP2R1A (1) 
NTRK2 (2), DHDDS (1), 
GABBR2 (1), GABRB2 (1), 
RAB11A (1), SNAP25 (1) 
  nonsense SCN1A (2), ANKRD11 (1),  HIVEP2 (1), IQSEC2 (2), NF1 (1), SYNGAP1 (1)  - 
  frameshift ARID1B (1 ), CDKL5 (1), IQSEC2 (1), KIAA2022 (1)  CLTC (1), NUS1 (1) 
  CSS SCN1A(1), SCN8A (1) - 
de novo CNVs (n=4) (n = 3) (n = 1) 
  deletions del(exons 21-23) of DNMT3A (1),  
del-encompassing PCDH19 (1) 
del(exon 2) of NUS1 (1) 
  duplications dup-encompassing UBE3A (1) - 
Inherited recessive 
SNVs/indels (n=6) 
(n= 6) (n = 0) 
  bi-allelic WWOX (1), SZT2 (1), NAGA (1), TBC1D24 (1) - 
  hemizygous SLC9A6 (1); IQSEC2 (1) - 
The number of individuals affected by pathogenic or likely pathogenic variants in the specified genes is indicated in parenthesis; CSS, canonical splice site variant. 
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Table 2. Summary of the clinical features in cases with DNMs in NTRK2 (NM_006180.4) 
Individua
l/Gender
/Agea 
De novo 
variant 
(detection) 
Cognitive 
and 
behavioral 
Epilepsy 
diagnosis 
Age at 
Seizure 
onset 
Seizure 
types 
AEDs EEG Brain MRI  Associated neurological features 
/seizure outcome  
HSC0103
/M/2y9
m 
c.1301A>G 
(p.Tyr434Cys) 
(WGSb) 
Severe 
GDD; 
IS 3 days  ES, Fo VGB, 
ACTH, LEV, 
CLB, TPM, 
VPA 
Modified 
hyps. 
Optic nerve 
hypoplasia 
Limb hypertonia and hyperreflexia; 
acquired microcephaly; visual 
impairment, swallowing difficulties, 
intractable seizures.  
indvSLIJ/ 
M/6y3m 
c.1301A>G: 
p.Tyr434Cys 
(cWESc) 
Severe ID; 
ASD;  
DEE 12hrs  with 
recurrence 
at 5 y  
M, FIA OXBZ, DZP DS and 
TIRDA 
Optic nerve 
hypoplasia 
Hypotonia; lower limbs spasticity; 
visual impairment; seizures controlled 
on OXBZ for one month. 
T25821/ 
F/4y7m 
c.1301A>G: 
p.Tyr434Cys 
(MIPs) 
Severe 
GDD and 
severe ID;  
IS 4 m  ES, To Prednisol., 
VGB, B6, 
LEV, CLB, 
TPM, LCM, 
KD, VPA, 
RFN, ZNS, 
CBD, DZP, 
PHT 
MF; Hyps. Optic nerve 
hypoplasia, 
myelination 
delay 
Acquired microcephaly; hypotonia; 
Subtle choreoathetosis; visual 
impairment; feeding difficulties; 
intractable seizures; high tolerance to 
painful stimuli (parents report). 
HF303/ 
M/4y3m 
c.1301A>G: 
p.Tyr434Cys 
(cWESc; WGSd) 
Severe 
GDD, 
suspected 
severe ID; 
ASD;  
IS 4 m ES, FIA PB, LEV, 
ACTH, 
VGB, CLB, 
ZNS, DZP, 
CBD 
DS, MF Optic nerve 
hypoplasia 
Limb hypotonia; visual impairment, 
swallowing difficulties, intractable 
seizures; high tolerance to painful 
stimuli (parents report). 
HSJ0335/
F/9y 
c.2159C>T : 
p.Thr720Ile 
(WGSb) 
GDD; 
mod.-
severe ID; 
ASD 
DEE 2.5 y 
(febrile sz 
at 23 m) 
Febrile, FIA, 
GTC, SE 
CLB, LEV, 
TPM, VPA, 
CBZ 
Normal; 
DS post 
status 
Delayed 
myelination, 
reduced WM, 
ventriculomeg
aly, thin CC 
Swallowing difficulties; hyperphagia 
after 3 years of age; seizure-free for 2 
years under CBZ. 
aage at last examination (years, y; months, m). bCENet. cGeneDx. dHudsonAlpha Study. cWES, clinical WES.  IS, infantile spasms; seizures: Fo, focal; FIA, focal impaired awareness; 
ES, epileptic spasms; M, myoclonus; To, tonic; GTC, generalized tonic-clonic.; SE, status epilepticus. AEDs, anti-epileptic therapies: ACTH, adrenocorticotropin; B6, vitamin B6; 
CBD, cannabidiol; CLB, clobazam; CBZ, carbamazepine; DZP, diazepam; KD, ketogenic diet; LCM, lacosamide; LEV, levetiracetam; OXBZ, oxcarbazepine; PB, phenobarbital; 
PHT, phenytoin; Prednisol., prednisolone; RFN, rufinamide; TPM, topiramate; VGB, vigabatrin; VPA, valproic acid; ZNS, zonisamide; underlined, treatment with clinical response 
(decreased seizure frequency or severity); in italics, negative response (aggravation of seizure frequency/severity). EEG: Hyps., hypsarrhythmia; DS, diffuse slowing; MF, multifocal; 
TIRDA, temporal intermittent rhythmic delta frequency activity;. MRI, magnetic resonance imaging: WM, white matter tracts; CC, corpus callosum. 
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Table 3. Summary of the clinical features in cases with DNMs in GABRB2 (NM_021911.2) 
Individua
l/Gender
/Agea 
De novo variant 
(detection) 
Cognitive/  
behavioral 
Epilepsy 
diagnosis 
Age at 
Seizure 
onset 
Seizure  
types 
AEDs EEG Brain MRI  Associated neurological features 
/seizure outcome 
1242500
/F/9.3y 
c.236T>C: 
p.Met79Thr 
(cWESe) 
GDD, 
Severe ID 
DEE 11 m A or FIA LEV Normal Arachnoid 
cyst 
Acquired microcephaly, axial 
hypotonia, spasticity, ataxia. Minor 
dysmorphic traits: short perineum,  
tapered fingers, short broad great 
toes; seizures controlled with LEV. 
K.02591/
F/10y 
c.373G>A: 
p.Asp125Asn 
(WESf) 
GDD, Mod. 
ID 
DEE 6 y Febrile, GTC VPA ND Normal Acquired microcephaly; seizure  
free  (responded to VPA, off 
medication). 
indvLB/ 
F/1.5y 
c.878G>C: 
p.Arg293Pro 
(WES) 
GDD No 
seizures 
NA NA NA Normal Normal Severe psychomotor delay, 
generalized dyskinesia, dystonia, 
cortical visual impairment. 
CNSA01
M/4y 
c.908A>G: 
p.Lys303Arg 
(targeted gene 
panel) 
GDD, 
Severe ID  
EOEE 1 day Fo, MF, To VPA, LEV, TPM, 
LTG  
MF, slow 
background 
Diffuse WM 
hyper T2 at 
birth and 
18m 
Acquired microcephaly, neonatal 
feeding difficulties, 
nonambulatory, hypotonia, 
spasticity, dystonia; rare seizures 
under TPM. 
T21213B 
F/ 14y 
6m 
c.911C>T: 
p.Ala304Val 
(MIPs) 
GDD, 
Severe ID 
DEE 4y M, A, At, non-
convulsive SE 
CLB, VGB, Pred, 
TPM, HCT, VPA, 
LTG, LEV, CZP, 
SULTH 
biF SW or sharp 
SW 
Normal Acquired microcephaly, 
nonambulatory, hypotonia, 
intractable seizures. 
HSJ0753/
F/4y 
c.730T>C: 
p.Tyr244His 
(WGSb) 
Severe 
GDD 
DEE 4m M, GTC, MSE LEV, VPA, TPM, 
B6, DZP, CLB, 
PB, PHT, CBD, 
KD 
biF SW; Hyps.; 
continuous 
diffuse SW 
Normal (9d 
and 1y) 
Acquired microcephaly, 
nonambulatory, axial hypotonia, 
spasticity, nystagmus, cortical 
visual impairment; intractable 
seizures. 
T23211/ 
F/5y1m 
c.730T>C: 
p.Tyr244His 
(MIPS) 
GDD, 
Severe ID 
DEE < 5 m To, Focal, 
autonomic, 
M, SE 
PB, LEV, CZP, 
P5P, B6, FOL, 
VGB, TPM, CBZ, 
NZP, OXBZ, VPA 
MF (biF 
predominant), 
slow background 
delay in 
myelination; 
reduction of 
white 
matter 
Congenital microcephaly, axial 
hypotonia, peripheral hypertonia, 
cortical visual impairment, 
choreoathetosis, dystonia, failure 
to thrive; intractable seizures. 
HA076/ 
M/15y8
m 
c.830T>C : 
p.Leu277Ser 
(WES) 
GDD, 
Severe ID  
DEE 4y8m M, At, A, GTC VPA, TPM, CZP, 
CLB, LEV, LTG 
slow; rhythmic 
notched slow 
waves 
At 2y: MF 
hyper T2 
WM; 
normal at 
4y and 9y 
Spasticity, poor coordination, 
broad-base gait; seizure control 
with LVT + LTG. 
33 
 
G64518/
F/10 y 
c.830T>C : 
p.Leu277Ser 
(WESf) 
GDD, 
Severe ID 
DEE  2y GTC, A, 
Febrile 
VPA, LTG high ampl. 
rhythmic slow 
waves 
Mild incr. LV 
at 2y; N at 3 
y 
Acquired microcephaly, brisk 
reflexes, seizure control with LTG. 
31841 
M/17d 
c.851C>A: 
p.Thr284Lys 
(WES) 
Severe 
GDD 
EME 7d M, To PB, LEV, MDZ, 
biotin, FOL, B6 
BS Normal Hypotonia, jitteriness, back 
arching, apneas, intractable 
seizures; deceased at age 17 days. 
3001866
/F/21m 
c.946G>A:  
p.Val316Ile 
(cWESe) 
Language 
delay 
DEE 12mo A or Fo, GTC LEV, OXBZ, CNZ, 
ZNS 
Normal Normal Apneas, neuroendocrine cell 
hyperplasia of infancy; intractable 
seizures. 
Individual 1242500 was also previously identified with a pathogenic de novo mutation in CHAMP1 (Isidor et al. 2016); aage at last examination (y, years; m, months; days, d). bCENet. 
eBCM-Miraca. fDDD Study. NA, not applicable. MAE, myoclonic astatic epilepsy. EME, early myoclonic encephalopathy. Seizures: A, absence; At, atonic, GTC, generalized tonic 
clonic; SE, status epilepticus; MSE, myoclonic status epilepticus. To, tonic, M, myoclonus. AEDs: CZP, clonazepam; FOL, folinic acid; HCT: hydrocortisone; LTG, lamotrigine; 
MDZ, midazolam; NZP, nitrazepam; P5P, pyridoxal 5-phosphate; Pred., prednisone; SULTH, sulthiam. EEG: biF, bi-frontal predominance; BS, burst-suppression; SW, spike wave. 
MRI: WM, white matter tracts; LV: lateral ventricles See footnote of Table 2 for other abbreviations. 
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Table 4. Summary of the clinical features in cases with DNMs in CLTC (NM_004859.3) 
Individual/G
ender/Agea 
De novo variant 
(detection) 
Cognitive/ 
behavioral 
Epilepsy 
diagnosis 
Age at 
Seizure 
onset 
Seizure 
types 
AEDs EEG Brain MRI  Associated neurological features /seizure 
outcome 
PBSD 
F/11y2m 
c.977_980delCAGT: 
p.Ser326Cysfs*8 
(cWESc) 
GDD, 
borderline 
IQ at 5y 
No 
seizures  
NA NA NA NA hyperT2 WM 
(Hypomyelinati
on) 
ADHD, impulsivity and poor socialization skills; 
Mild hypotonia; wide-based gait. 
5289183 
M/20y5m 
c.1660_1668del: 
p.Met554_Tyr556del 
(cWESc) 
Borderline 
IQ, learning 
disabilities 
NA 14y 1 seizure  LEV Normal Normal Progressive paraparesis with LL spasticity, ataxia, 
myoclonus. One seizure without recurrence 
under LEV. Seizure-free for 4 years off meds. 
indvAA 
M/3y2m 
c.2669C>T: 
p.Pro890Leu (cWESg) 
GDD No 
seizures 
NA NA NA Normal Normal Mild ataxia and possibly myoclonus. 
CAUSES1/M/
4y7m 
c.2669C>T: 
p.Pro890Leu (WES) 
GDD, 
suspected 
ID 
No 
seizures  
NA NA NA NA Normal Mild hypotonia, oral and motor apraxia 
suspected ADHD. 
18052017/
F/30y 
c.2669C>T: 
p.Pro890Leu (WESh) 
Mod. ID No 
seizures  
NA NA NA Normal Normal Bradykinesia, bradypsychism,  hypomimia,  
hypokinesia, clumsiness, attention instability.  
indvPAR/M/
16y 
 
 
c.3140T>C: 
p.Leu1047Pro 
(trio cWES) 
Severe ID DEE 1 yr Suspecte
d FIA 
VPA Non 
specific 
irritative 
pattern, 
no foci 
thin, short 
corpus 
callosum, with 
hypoplasia of 
its posterior 
part, wide 
Virchow-Robin 
spaces 
Neonatal-onset hypotonia, noneverbal, acquired 
microcephaly, severe gastroinstestinal reflux; 
seizure-free under VPA. 
273692 
M/4y 
c.3322T>C: 
p.Trp1108Arg (WESf) 
Severe 
GDD, 
suspected 
severe ID 
DEE 2y M, GTC, 
gelastic 
seizures? 
LEV abnormal Pontocerebellar 
atrophy; 
delayed 
myelination  
Non ambulatory; spasticity; dystonia; myoclonus; 
neonatal feeding difficulties; visual impairment; 
seizure control with LEV. 
DDD261801 
M/10y7m 
c.3595C>T: 
p.Gln1199* (WESf) 
Mild GDD, 
Mild ID 
No 
seizures 
NA NA NA NA Normal Neonatal-onset hypotonia, congenital ptosis, 
poor social skills. 
indvMB 
F/7.5y 
c.3621_3623del: 
p.Asp1207del  (WES) 
GDD, 
Severe ID  
DEE 3y Febrile 
GTC, M, 
To 
VPA, 
LTG, CLB, 
CZP, LEV, 
TPM, 
LCM 
M SW, biF  Thin CC; 
hyperT2 WM, 
enlarged LV 
Acquired microcephaly, severe hypotonia; ataxia; 
oral and motor apraxia. Intractable seizures. 
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HSC0054 
F/23y 
c.4575dupA: 
p.Glu1526Argfs*18 
(WGSb) 
GDD, mod. 
ID 
 
DEE 5m A, M, To, 
GTC, Fo 
CLB, 
VPA,HCT
Z, LEV, 
LTG, KD 
gen SW 
and PSW 
Delayed 
myelination. 
Normal at 20y 
Neonatal hypotonia; scoliosis, Intractable 
seizures until puberty. Seizure-free under LEV 
and LTG. 
LDKQS 
M/12y10m 
c.4605+2T>C 
(c.WESc) 
GDD, mod. 
ID 
No 
seizures 
NA NA NA NA Normal Hypotonia, neonatal feeding difficulties, 
sensorineural hearing loss. 
DDD0280 
F/6y 
c.4663C>T 
p.Gln1555* (WESf) 
GDD, mod.-
severe ID 
No 
seizures 
NA NA NA NA ND Hypotonia. 
281177 
M/11y 
c.4667G>A: 
p.Trp1556*(WESf) 
Mod. ID No 
seizures 
NA NA NA NA ND Neonatal hypotonia. 
aage at last examination (y, years; m, months). cGeneDx. gRadboud UMC. fDDD Study. bCENet. hOPBG. NA: not-available or not-applicable. ND: not done. HCTZ: 
hydrochlorothiazide. EEG: MSW, multifocal spike-wave; biF, bi-frontal predominance, gen. SW, generalized spike-wave; PSW, poly-spike and wave. NA, not applicable. ND, not 
done. See footnotes of Tables 2, 3 for other abbreviations. 
 
 
Table 5. Summary of the clinical features in cases with DNMs in DHDDS (NM_024887.3) and NUS1 (NM_138459.4) 
ID/Gend
er/Agea 
Gene De novo variant 
(detection) 
Cognitive/  
behavioral 
Epilepsy 
diagnosis 
Age at 
Seizure 
onset 
Seizure 
types 
AEDs EEG Brain MRI  Associated neurological features /seizure 
outcome  
indvSG/ 
F/5y1m 
DHDDS c.110G>A: 
p.Arg37His 
(c.WESe) 
GDD, severe 
ID 
DEE 
18m 
MA photo, 
GTC, 
febrile Fo 
VPA, 
LTG, LEV, 
ETH, VPA 
gen. SW, 
photo+ 
Normal Hypotonia; short stature, intractable 
seizures. 
HSJ0762/ 
M/5y6m 
DHDDS c.110G>A: 
p.Arg37His 
(WGSb) 
GDD DEE 1y M, A, At, 
fever- 
sensitive 
LEV, VPA  gen. SW, 
diffuse 
slowing 
Normal Hypotonia, tremor, wide-based gate, 
ataxia. Seizure-free x 1 year on VPA. 
indvEF/ 
F/5y6m 
DHDDS c.632G>A: 
p.Arg211Gln 
(c.WESc) 
GDD, 
borderline IQ 
DEE 4y MA LEV, LTG, 
OXBZ 
epileptif
orm 
Normal;  
Chiari I 
malformation 
Hypotonia, tremor, ataxia, inattention, 
obesity; seizures controlled with OXBZ. 
MDB318
82/M/35 
DHDDS c.632G>A: 
p.Arg211Gln 
(WESh) 
GDD, severe 
ID 
DEE 6-9y Myoclonic VPA, 
benzodia
zepines 
gen. PSW  Normal Generalized tremor, facial myokimia, 
bradykinesia, hypomimia, rigidity, freezing  
and impaired postural reactions, frontal 
lobe impairment features. Seizure free 
since the age of 9y. Current therapy: VPA, 
Clonazepam, Tetrabenazine.   Normal 
glycosylation assay. 
indvNCJ/
F/7y1m 
DHDDS c.632G>A: 
p.Arg211Gln 
(c.WESg) 
GDD, mod-
severe ID 
NA 7y M None Normal Normal Ataxia, myoclonus, tremor, dystonia, short 
stature; no treatment initiated yet for 
cortical myoclonus. Normal glycosylation 
assay. 
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indvKW/
M/7y11
m 
NUS1 c.743delA: 
p.Asp248Alafs 
(c.WESc) 
GDD, severe 
ID 
DEE 12m M, GTC LEV BiF 
epileptif
orm 
Normal Ataxia with LEV. Lack of coordination. 
Seizures controlled with LEV. 
HSJ0623/
M/15y 
NUS1 c.128_141dup: 
p.Val48Profs*7 
(WGSb) 
GDD, mod. 
ID, ASD 
DEE 10m MA, At, 
Febrile 
GTC 
VPA, 
LTG, LEV, 
ETH, CZP, 
CBZ, Stiri. 
CLB 
Diffuse 
slowing, 
BiF or 
gen. 
spikes  
Normal ADHD, tremor. Seizures controlled under 
VPA/CLB. 
HSJ0627/
F/20y 
NUS1 exon2-deletion 
(WGSb) 
Motor delay, 
mild ID 
DEE 2.5y M status, 
MA, At 
VPA, LEV, 
CLB, FEL, 
LTG, CZP  
gen. SW 
and PSW 
Normal Tremor, dysarthria. Seizures controlled on 
VPA/LTG/CZP. 
1age at last examination (years, y; months, m); eBCM, bCENet, cGeneDx, gRadboud UMC. Seizure types: MA, myoclonic absence; MA photo: myoclonic absences with 
photosensitivity; GTC: generalized tonic-clonic; Fo, focal; M, myoclonic; A. absences; At, atonic. AED: FEL, Felbamate; OXBZ, oxcarbazepine; Stiri, stiripentol. See footnotes of 
Tables 2, 3 for other abbreviations. 
 
 
Table 6. Genes enriched in DNMs in the DEE cohorts 
 de novo LoF variants de novo functional variants 
gene observed expected p-value c.p-value observed expected p-value c.p-value 
CDKL5 3 0 8.57E-09 0.0003 5 0 8.90E-10 3.49E-05 
DNM1 0 0 1 1 6 0 1.03E-11 4.04E-07 
GABRB3 0 0 1 1 4 0 7.58E-09 0.0003 
GNAO1 0 0 1 1 4 0 4.47E-09 0.0002 
IQSEC2 3 0 6.76E-09 0.00026 3 0 1.14E-05 0.45 
KCNQ2 0 0 1 1 4 0 1.69E-07 0.007 
KCNT1 0 0 1 1 4 0.1 9.12E-07 0.036 
SCN1A 7 0 1.84E-17 7.2E-13 14 0.1 6.37E-27 2.5E-22 
SCN2A 0 0 1 1 7 0.1 3.81E-12 1.49E-07 
SCN8A 1 0 0.007 1 7 0.1 3.08E-12 1.21E-07 
SLC35A2 2 0 4.74E-07 0.018 3 0 4.89E-07 0.019 
STXBP1 1 0 0.006 1 6 0 1.27E-12 4.98E-08 
c.p-value, corrected p-value = p-value x 2 x 19618 (significant < 0.05, in bold). LoF: nonsense, frameshift and CSS de novo variants. Functional: LoF + missense variants 
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Table 7.  Summary of the clinical features in cases with DNMs in RAB11A (NM_004663.4), GABBR2 (NM_005458.7) and SNAP25 (NM_003081.3) 
Individual
/Gender/
Agea 
Gene De novo 
variant 
(detection) 
Cognitive/ 
behavioral 
Epilepsy 
diagnosis 
Age at 
Seizure 
onset 
Seizure 
types 
AEDs EEG Brain MRI  Associated neurological features 
/seizure outcome  
HK055/M/
5.5y 
RAB11A c.71A>G: 
p.Lys24Arg 
(WES) 
GDD, 
Mod. ID 
No 
seizures 
NA NA NA Abnormal 
background 
activity, but 
no epileptic 
charges 
Central brain 
atrophy and 
bilateral 
periventricular 
white matter 
damage, thin 
CC 
Acquired microcephaly, axial 
hypotonia, obesity, aggressive 
behavior. 
HSJ0637/F
/9.5y 
RAB11A c.244C>T: 
p.Arg82Cys 
(WGSb) 
GDD, 
Severe ID 
IS 4m M, ES, Fo NZP, CLB, 
VGB, TPM, 
CLB, VPA, 
LEV 
Modified 
Hyps.; M; 
Diffuse 
slowing with 
M spikes 
Atrophy, 
partial 
agenesis of 
CC, delayed 
myelination. 
Decrease NAA  
Acquired microcephaly, axial 
hypotonia. 
24631/M/
4y 
RAB11A c.461C>T: 
p.Ser154Leu
(WESf) 
mod. GDD No 
seizures 
NA NA NA NA partial 
agenesis of 
the CC 
Distractible, ADHD? 
84049/F/9
y/11m 
RAB11A c.461C>T: 
p.Ser154Leu
(WESf) 
mod. ID No 
seizures 
NA NA NA NA ND Possible hyperactivity. Obesity. 
HSJ0048/
M/14 
GABBR2 c.2077G>T: 
p.Gly693Trp
(WGSb) 
Severe 
GDD, 
severe ID 
DEE, IS 11m FIA, ES, 
GTC 
CBZ, VGB, 
VPA, TPM, 
CLB, PHT, 
LEV, LCM, 
LTG 
Modified 
Hyps. 
Increased sub-
arachnoid 
spaces 
Axial and limb hypotonia, 
hyporeflexia, scoliosis, 
hypersalivation. 
HSJ0745/
M/23y 
SNAP25 c.496G>T: 
p.Asp166Tyr
(WGSb) 
GDD, mod. 
ID 
DEE 18m GTC, FIA VPA, CLB gen. SW, 
CSWS 
mild diffuse 
cortical 
atrophy 
Apneas, bradycardia, severe 
constipation. Minor dysmorphic 
traits. Seizure-free x 2y on VPA. 
aage at last examination (years, y; months, m). bCENet. fDDD Study.  CSWS, continuous spike and-wave during sleep. NAA, N-acetylaspartate. See footnotes of Tables 2, 3 for other 
abbreviations. 
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TM Shc IGC2-1 IGC2-2 LRRCT LRR LRRNT 
SP 
p.Tyr434Cys p.Thr720Ile 
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